FDA Safety Center Authority Would Extend To OTCs Under Grassley Bill
This article was originally published in The Tan Sheet
Executive Summary
A new safety center proposed in Sen. Charles Grassley's "FDA Safety Act" (FDASA) would have broad postmarket authority over some over-the-counter drugs, as well as prescription pharmaceuticals and biologics
You may also be interested in...
FDA Senior Staff Has Final Say Over Disputes In Enzi/Kennedy Bill
Senior FDA officials will have final say over drug safety disputes under proposed legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.)
FDA Senior Staff Has Final Say Over Disputes In Enzi/Kennedy Bill
Senior FDA officials will have final say over drug safety disputes under proposed legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.)
FDA Senior Staff Has Final Say Over Disputes In Enzi/Kennedy Bill
Senior FDA officials will have final say over drug safety disputes under proposed legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.)